000 nab a22 7a 4500
999 _c16802
_d16802
003 PC16802
005 20220404121743.0
008 220404b xxu||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _9576
_aMorales Cerdán, José María
_eNefrología
100 _92597
_aMartinez-Flores, Jose A.
_eInstituto de Investigación i+12
100 _92598
_aSerrano, Manuel
_eInstituto de Investigación i+12
100 _92010
_aCastro Panete, María José
_eInmunología
100 _92596
_aAlfaro, Javier
_eInstituto de Investigación i+12
100 _91504
_aGarcía Martín, Florencio
_eNefrología
100 _91220
_aMartínez González, Miguel Ángel
_eAnatomía Patológica
100 _91321
_aAndrés Belmonte, Amado
_eNefrología
100 _91487
_aGonzález Monte, Esther
_eNefrología
100 _91488
_aPraga Terente, Manuel
_eNefrología
100 _91510
_aPaz Artal, Estela
_eInmunología
100 _9661
_aSerrano Hernández, Antonio
_eInmunología
245 0 0 _aAssociation of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I.
_h[artículo]
260 _bJournal of the American Society of Nephrology : JASN,
_c2015
300 _a26(3):735-45.
500 _aFormato Vancouver: Morales JM, Martínez Flores JA, Serrano M, Castro MJ, Alfaro FJ, García F et al. Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I. J Am Soc Nephrol. 2015 Mar;26(3):735-45.
501 _aPMCID: PMC4341482
504 _aContiene 56 referencias
520 _aIn the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti-β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation.
710 _9625
_aInstituto de Investigación imas12
710 _986
_aServicio de Nefrología
710 _9395
_aServicio de Inmunología
710 _9330
_aServicio de Anatomía Patológica
856 _uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341482/
_yAcceso libre
942 _2ddc
_cART
_n0